Phaseline

Companies › D2M Biotherapeutics

D2M Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DM919
Anti-MICA/MICB monoclonal antibody
MICA, MICBPhase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06328673DM919Phase 1Advanced Solid TumorOncologyMar 2026

Targets

MICA (1) MICB (1)

Companies with the same targets

Cullinan Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.